Literature DB >> 27742656

Pembrolizumab induced severe sclerodermoid reaction.

N Shenoy1, B Esplin1, N Barbosa2, C Wieland2, U Thanarajasingam3, S Markovic1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 27742656     DOI： 10.1093/annonc/mdw543

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  3 in total

Review 1.  Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.

Authors:  Samantha R Ellis; Aren T Vierra; Jillian W Millsop; Mario E Lacouture; Maija Kiuru
Journal:  J Am Acad Dermatol       Date:  2020-04-29       Impact factor: 11.527

2.  Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy.

Authors:  Marie Kostine; Marie-Elise Truchetet; Thierry Schaeverbeke
Journal:  Rheumatology (Oxford)       Date:  2019-12-01       Impact factor: 7.580

3.  Management of rheumatic complications of ICI therapy: a rheumatology viewpoint.

Authors:  Jan Leipe; Xavier Mariette
Journal:  Rheumatology (Oxford)       Date:  2019-12-01       Impact factor: 7.580
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.